
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc demonstrated a strong financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, which marked a significant increase of 105% quarter-over-quarter from the previous quarter's $2.06 million. The company also experienced an improvement in gross margins, rising to 60.3% compared to 39.8% in the second quarter of 2025, indicating enhanced operational efficiency. Furthermore, the announcement of a non-binding merger agreement with Applied Digital Cloud suggests potential for strategic growth and expansion, enhancing the overall positive outlook for Ekso Bionics in the healthcare and industrial exoskeleton technology markets.
Bears say
Ekso Bionics Holdings Inc experienced a revenue shortfall in the previous quarter, primarily attributed to two significant order delays in its Enterprise Health segment, resulting in a missed consensus expectation by $1.5 million. The company reported revenues of $4.23 million in 3Q25, with a net loss of $0.54 per share, which, while slightly better than the consensus estimate, still indicates ongoing financial challenges. Additionally, the downgrade to a Neutral rating and the removal of a previous price target reflect growing concerns about the company's ability to stabilize and grow its revenue amid these operational setbacks.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares